

Trust Headquarters
 Russell's Hall Hospital
 Dudley
 West Midlands
 DY1 2HQ

Ref: FOI-022026-0002217

Date: 25.03.2026

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

Q1. How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to? **16**

Q2. How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

- BR (Bendamustine + rituximab) **1**
- VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) **0**
- R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) **0**
- R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) **4**
- CVP (cyclophosphamide, vincristine and prednisolone) **0**
- Brukinsa (zanubrutinib) **1**
- Imbruvica (ibrutinib) **4**
- Velcade (bortezomib) + chemotherapy **0**
- Tecartus (brexucabtegene autoleucel) **0**
- R-BAC (rituximab, bendamustine and cytarabine) **0**
- R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) **0**
- Any other systemic anti-cancer therapy **7**
- Wait and watch (monitoring only, no active treatment) **Only active recorded in cEPMA system**

Q3. How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

For this question, please only count patients that have received the below treatments for the first time.

- BR (Bendamustine + rituximab) **1**
- VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) **0**
- R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) **0**
- R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) **1**
- CVP (cyclophosphamide, vincristine and prednisolone) **0**
- Brukinsa (zanubrutinib) **1**

- Imbruvica (ibrutinib) 0
- Velcade (bortezomib) + chemotherapy 0
- Tecartus (CAR-T) 0
- R-BAC (rituximab, bendamustine and cytarabine) 0
- R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) 0
- Any other systemic anti-cancer therapy 1
- Wait and watch (monitoring only, no active treatment) **Only active recorded in cEPMA system**

Q4. If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials. **None at this time**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team
The Dudley Group NHS Foundation Trust**